Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-006: Lenvatinib plus Keytruda and chemotherapy in 1L metastatic nonsquamous NSCLC
NCT03829319Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2019
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of lenvatinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Merck & Co. Primary endpoints: Number of Participants With a Dose-limiting Toxicity at 21 days, Number of Participants Who Experienced an Adverse Event at 48 months and 3 more. Started Mar 2019; status: completed.
02
Drugs
lenvatinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03829319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829319.